Harrow Brings Back TRIESENCE: A Game-Changer in Eyecare
Harrow Reintroduces TRIESENCE to Market
Nashville, Tennessee - Harrow (NASDAQ: HROW), a leading pharmaceutical company focused on eyecare, is thrilled to reintroduce TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL to the healthcare market. This vital product has been off the market for over five years, primarily due to supply chain constraints. It is a preservative-free corticosteroid approved by the U.S. Food and Drug Administration (FDA), designed specifically for use in vitrectomy procedures and for treating ocular conditions that do not respond adequately to topical steroids.
CEO's Vision for Growth
The CEO of Harrow, Mark L. Baum, expressed his excitement about TRIESENCE's return, noting the extensive international cooperation that was key to rebuilding the supply chain. Baum believes that the product's resurgence will significantly impact the eye health of many Americans by improving access to essential medication.
Significance in Ophthalmology
Ophthalmologists across the country have greeted TRIESENCE's arrival with enthusiasm. They stress its critical role in enhancing surgical visibility and effectively treating severe inflammatory eye conditions. Renowned professionals, such as Dr. Rishi Singh from Cleveland Clinic Florida and Dr. John W. Kitchens from Retina Associates of Kentucky, highlighted how the absence of TRIESENCE had forced them to utilize less effective alternatives in their practices.
Availability and Ordering
After being listed on the FDA Drug Shortage List for more than five years, TRIESENCE is now available for ordering through major pharmaceutical specialty distributors. The product comes in single-use vials and is conveniently associated with two National Drug Codes, simplifying its ordering process for healthcare providers.
Commitment to Eyecare
Harrow, Inc. remains steadfast in its mission to develop and market innovative ophthalmic pharmaceuticals throughout North America. The company strives to ensure that both prescription and non-prescription products are accessible and affordable, supporting the preservation of sight for patients every year.
Corporate Expansion and Growth
Recently, Harrow Inc. also announced its intent to expand its corporate headquarters in Nashville, which is projected to generate nearly 150 new employment opportunities. This decision is prompted by the company’s impressive quarterly revenue of $48.9 million, reflecting a remarkable 46% year-over-year growth.
Financial Performance and Future Outlook
As Harrow continues to scale up its operations, its branded revenue has outpaced compounded revenue, resulting in higher profit margins. Products such as IHEEZO and TRIESENCE, along with VEVYE, targeting dry eye disease, are experiencing significant growth, including a notable 212% increase in VEVYE prescriptions during Q2. CEO Baum has indicated plans to bolster the VEVYE salesforce and reintroduce TRIESENCE by the fourth quarter of the following year. Furthermore, he anticipates that the revenue for the upcoming year could surpass $180 million.
Strategic and Cautious Approach
Although these advancements indicate strong financial health and growth potential, Harrow Health has adopted a disciplined approach towards product launches and investments. The company is keen on avoiding overpayment for new products to enhance its portfolio.
Market Insights
The timing of TRIESENCE's reintroduction aligns with Harrow's current trajectory of significant growth and increased market attention. Data indicates that Harrow's revenue growth reached an impressive 50.06% over the past year, with quarterly revenue growth hitting 46.22% during Q2 2023. Such robust performance coincides with their strategic move to bring back this essential product.
Challenges Ahead
Despite the encouraging financial indicators, Harrow has faced challenges, as it has not been profitable over the last twelve months, and analysts do not expect profitability for the current year. This reality signifies that even though the reintroduction of TRIESENCE® may provide a revenue boost, the company's primary focus remains on expansion and growth rather than immediate profit margins.
Frequently Asked Questions
What is TRIESENCE and what conditions does it treat?
TRIESENCE is a corticosteroid approved by the FDA, primarily used for vitrectomy procedures and for treating ocular conditions that do not respond to topical steroids.
Why was TRIESENCE unavailable for several years?
The product was off the market for over five years due to supply chain issues that affected its availability.
Who is Harrow and what is their mission?
Harrow is a North American pharmaceutical company focused on eyecare, aiming to make both prescription and non-prescription products accessible and affordable for patients.
What recent financial achievements has Harrow reported?
Harrow has reported a record quarterly revenue of $48.9 million, showcasing a year-over-year growth of 46% and a significant revenue increase across its product lines.
What are Harrow's future plans concerning TRIESENCE?
The company plans to reintroduce TRIESENCE in the fourth quarter of the following year and anticipates that its revenue for the next year may exceed $180 million.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Understanding Oil's Impact on Inflation and Central Banks
- Cambria Partners with ETF Architect to Transform Tax Efficiency
- Uber Partners with Avride to Enhance Food Deliveries and Rides
- Wavin Launches New Production Facility to Boost Water Solutions
- Constellation Brands Surges with Strong Beer Demand Results
- Hansard Global PLC Innovates with Majesco LifePlus Solutions
- EVgo Inc Soars with Conditional Loan Guarantee and Upgrade
- Godspeed Capital Expands ICE USA with RGC&A Partnership
- Berkshire Hathaway Adjusts Portfolio, Sells Bank of America Shares
- Counterpart Enhances Insurance Offerings with New GL Insurance
Recent Articles
- Family Dollar Partners with Instacart for SNAP Online Payments
- Innovative Robotic Laser Cleaner Presented by Laser Photonics
- Crayon's Regina Manfredi Celebrated for Leadership in Tech
- Shanghai Tourism Festival: A Vibrant Celebration of Cultures
- AstraZeneca's CALQUENCE: A Game Changer for Untreated MCL
- Mammoth Energy Eliminates Debt and Expands Future Investments
- Canadian Solar Strengthens Portfolio with BlackRock Investment
- DTI's Acquisition of EDP Expands Global Drilling Capabilities
- Enbridge's Strategic Pipeline Ventures in the Gulf of Mexico
- Avidity Biosciences' DM1 Drug Trial Receives FDA Approval
- Canadian Dollar Expected to Rise: Economic Trends for 2025
- SSE plc Sees Share Price Surge Following Trading Update
- Stellantis Faces Profound Challenges Amid Dividend Concerns
- Exciting Growth Stocks to Consider for Future Investments
- Missouri American Water Funds Critical Firefighter Initiatives
- Southland Secures $160 Million Credit Facility for Expansion
- Harnessing GenAI for Business Growth: Tools and Solutions
- Mammoth Energy Surpasses Debt Obligations and Boosts Capex Plans
- Family Dollar Partners with Instacart for Enhanced SNAP Payments
- BioCryst Pharmaceuticals Announces New Employee Stock Grants
- New Study Reveals Urgent Need for Improved Global Water Security
- Ginkgo Bioworks and Virica Biotech Join Forces for AAV Excellence
- Goliath Resources Secures $16.1 Million in Latest Financing
- Leadership Transition at USA Compression Partners: A New Era Begins
- Howard Hughes Breaks Ground on Luxury Ritz-Carlton Homes
- A Toast to Flavor: Swiss Miss and Hotel Tango's Bold Bourbon
- DTI Expands Global Reach with European Drilling Projects Acquisition
- First Foundation Inc. Transitions $1.9 Billion Portfolio to Loans
- Ennu Celebrates Recognition and Strategic Leadership Change in Growth
- Insights on Vehicle Alerts Impacting Driver Assistance Systems
- Enbridge Expands Pipeline Operations for bp's Deepwater Project
- Meketa Capital Unveils New Infrastructure Fund for Advisors
- Boardwalk REIT Updates on Housing Demand and Q3 Insights
- Bellevue Capital Partners Expands Shareholding in GNL Holdings
- Navigating Geopolitical Challenges: International SOS Insights
- Survey Highlights Valuable ROI for Graduates from Risepoint
- Darktrace Transforms Cloud Security with Real-Time Innovations
- Explore Top Consumer Stocks Poised for Recovery This Quarter
- Exciting Upcoming Bible Seminar by Shincheonji Church of Jesus
- Goliath Resources Secures $16.1M in Strategic Financing
- BCE Inc. Announces Third-Quarter Results Conference Call
- Ben Sexton Honored with AI Innovation Award for eDiscovery Excellence
- Ionis Pharmaceuticals Unveils New Data on Donidalorsen at ACAAI
- Avidity Biosciences Advances Delpacibart Etedesiran's Journey
- Enhancing Your Home's Air Quality: Tips for Healthier Living
- GFL Environmental Expands Dividend Strategy Amid Growth Plans
- Saudi National Orchestra Captivates UK Audience with Music
- PostNet Achieves Notable Ranking in Franchise Times Top 400 List
- Discover Club House®'s New Audio Cookbook Featuring Gerry Dee
- Pharvaris Unveils Promising Research on HAE Treatments